# OnCo record ahod1331 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ahod1331/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ahod1331", "NCT02166463" ;
  schema:name "AHOD1331"@en ;
  schema:alternateName "COG AHOD1331"@en ;
  schema:description "AHOD1331 showed that replacing bleomycin with the antibody-drug conjugate brentuximab vedotin in the chemotherapy given to children and teenagers with advanced Hodgkin lymphoma cut relapses by more than half without extra side effects, and it became the new standard for high-risk disease."@en ;
  schema:url <https://onco.cc/trials/ahod1331/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02166463> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/childhood-cancers/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/bleomycin/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/> .